Cell Biotech Co., Ltd
KKRX:04996014,990.00
KRW
-150.00
(-0.99%)
ISIN
KR7049960008
Return %
Stock
S&P 500
1Y
25.44
14.20
3Y
35.41
81.12
5Y
-15.79
68.34
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Myoung-Joon Jeong
- Full Time Employees
- 123
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Gimpo-si South Korea
- IPO Date
- Dec 13, 2002
- Website
- cellbiotech.com
- Similar Companies
- Business
- Cell Biotech Co., Ltd. is a South Korea-based biotechnology company that specializes in the research, development, fermentation, manufacturing, and global commercialization of microbiome-based probiotics, dietary supplements, derma-cosmetics, and live biotherapeutic products. Founded in 1995 and headquartered in Gimpo-si, South Korea, the company operates across both business-to-consumer (B2C) and business-to-business (B2B) sectors, serving healthcare, pharmaceutical, and consumer markets worldwide. The company's core product and service portfolio includes finished probiotic health functional food formulations marketed under its flagship DUOLAC brand, providing specialized gastrointestinal, immune, and metabolic support for infants, children, adults, and seniors; pharmacy- and hospital-exclusive probiotic solutions marketed under the Nutra DUOLAC brand; microbiome-driven skincare and derma-cosmetic formulations sold under the LACTOClear brand, incorporating patented lactic acid bacteria-derived bacteriocin technologies; bulk raw probiotic strain powders, customized premixes, and contract manufacturing services supplied to dietary supplement and pharmaceutical manufacturers under the LAB2PRO brand; and next-generation sequencing (NGS)-based personalized gut microbiome analysis and profiling services. Cell Biotech’s formulations utilize its proprietary, globally patented Dual Coating technology, engineered to protect live bacterial strains against gastric acid and bile salts for targeted intestinal delivery. The company distributes its products across domestic channels and exports to over 55 countries throughout Europe, Asia-Pacific, North America, and the Middle East, supported by regional subsidiaries including Cell Biotech International A/S in Denmark and Cell Biotech France. In recent corporate and operational developments, Cell Biotech has accelerated its strategic expansion into microbiome-based biopharmaceuticals through the development of PP-P8, a first-in-class oral recombinant microbiome gene therapy for colorectal cancer based on the engineered Pediococcus pentosaceus CBT-SL4 strain expressing the therapeutic P8 anti-cancer protein. Following Phase 1 clinical trial approval from the South Korean Ministry of Food and Drug Safety, the company initiated patient dosing in its Phase 1 clinical study in partnership with Seoul National University Hospital. Additionally, Cell Biotech has broadened the research scope of its proprietary Probiotics Drug Delivery System (DDS) platform to encompass metabolic syndrome, diabetes, and gynecological health, while expanding its commercial functional food line with newly validated strains targeting visceral and hepatic lipid metabolism.